MetaCap

Fulgent Genetics Inc. (FLGT)

NASDAQ: FLGTHealth CareMedical SpecialitiesUSD

24.12-0.66 (-2.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FLGT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$673.89M
EPS (TTM)
-$3.10
52-week range
13.46 – 31.04
Day range
23.88 – 24.79
Volume / Avg
322.97K / 330.28K
Beta
—

52-week range

$13.46$31.04

FLGT stock today

On Nov 20, FLGT ended the session at $24.12, shedding $0.66 (2.66%), versus the S&P 500's 3.70% decline. Shares are 22.3% below their 52-week high of $31.04, set on Nov 25, 2025 and 79.2% above the 52-week low of $13.46, in the middle of the past year's range. FLGT is down 8.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 19.6%.

Fulgent Genetics has posted a net loss over the last twelve months (EPS of -$3.10), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Fulgent Genetics

Company profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.

Industry
Medical Specialities
CEO
Mr. Ming Hsieh
Headquarters
El Monte, CA
Employees
1,315
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Fulgent Genetics generated $322.7 million in revenue, up 13.8% from fiscal 2024. Fulgent Genetics reported a net loss of $60.5 million, compared with a loss of $42.7 million a year earlier. Gross margin was 40.6% (up from 37.8%) and operating margin -28.2%.

Fulgent Genetics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$322.67M$283.47M$289.21M$618.97M$992.58M
Growth+13.83%-1.99%-53.27%-37.64%+135.37%
Net income$-60.51M$-42.71M$-167.82M$143.40M$507.36M
EPS (diluted)$-1.97$-1.41$-5.63$4.63$16.38

Analyst forecast

Forecast

Consensus (1 analysts)

hold

Avg. price target

$25.00+3.65%

  • Strong buy 0
  • Buy 0
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.48 vs $1.00
Surprise
-148.00%

FLGT news

All FLGT news

Fulgent Genetics peers

Health Care sector
FLGT peer companies
CompanyPrice% ChgMarket capCompare
YDESYD Bio Limited4.83+5.92%$342.12Mvs FLGT
CSTLCastle Biosciences Inc.32.86-1.63%$1.01Bvs FLGT
FRNMFreenome Inc.9.36-5.69%$1.04Bvs FLGT
TLSITriSalus Life Sciences Inc.2.32+6.67%$143.14Mvs FLGT
BNRBurning Rock Biotech Limited ADR13.24-0.60%$139.63Mvs FLGT
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs FLGT
XGNExagen Inc.3.61-5.00%$92.10Mvs FLGT
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs FLGT

Indexes, lists and sector

Fulgent Genetics stock FAQ

What is Fulgent Genetics's stock price today?

FLGT last traded at $24.12 as of Nov 20, 4:00 PM EST, down 2.66% on the day. Prices are delayed at least 15 minutes.

Who is Fulgent Genetics's CEO?

Mr. Ming Hsieh is the chief executive officer of Fulgent Genetics Inc., which has about 1,315 employees.

What is the FLGT 52-week high?

The 52-week high for FLGT is $31.04 and the 52-week low is $13.46. The stock is currently 22.3% below its high.

Compare FLGT